intervention group :Sintilimab injection (200mg, Q3W, intravenous infusion, 1 cycle every 21 days, administered on the first day of each cycle) combined with arsenic trioxide injection (10mg, Q3W, int

2 trials

Sponsors

The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital)

Conditions

Hepatocellular carcinomaIntrahepatic Cholangiocarcinoma

Phase 2

A single arm phase II clinical study of ATO combined with PD-1 inhibitor in the treatment of unresectable advanced intrahepatic cholangiocarcinoma with TP53 gene mutation

Active, not recruitingChiCTR2300071033

The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital)Intrahepatic Cholangiocarcinoma

Start: 2023-05-10Updated: 2023-06-04

A single arm phase II clinical study of ATO combined with PD-1 inhibitor in the treatment of unresectable advanced hepatocellular carcinoma with TP53 gene mutation

RecruitingChiCTR2300073941

The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital)Hepatocellular carcinoma

Start: 2023-07-31Updated: 2023-07-30